-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 MWg8zLlrwKUP2JoQbFJ5H8avmIOGtjgO4wx+xqw8H1CgVXrjvWOwOjGpJhQqCke/
 I02ZywhvSuljjubZZEHb9Q==

<SEC-DOCUMENT>0001193125-07-159869.txt : 20070723
<SEC-HEADER>0001193125-07-159869.hdr.sgml : 20070723
<ACCEPTANCE-DATETIME>20070723170402
ACCESSION NUMBER:		0001193125-07-159869
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20070723
FILED AS OF DATE:		20070723
DATE AS OF CHANGE:		20070723

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			QIAGEN NV
		CENTRAL INDEX KEY:			0001015820
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-28564
		FILM NUMBER:		07994215

	BUSINESS ADDRESS:	
		STREET 1:		SPOORSTRAAT 50
		CITY:			KJ VENLO
		STATE:			P7
		ZIP:			5911
		BUSINESS PHONE:		31-77-320-8400

	MAIL ADDRESS:	
		STREET 1:		SPOORSTRAAT 50
		CITY:			KJ VENLO
		STATE:			P7
		ZIP:			5911
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<HR SIZE="3" NOSHADE COLOR="#000000" ALIGN="left"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><HR WIDTH="17%" SIZE="1" NOSHADE COLOR="#000000"> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="5"><B>FORM 6-K </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Report of Foreign Private Issuer </B></FONT></P> <P
STYLE="margin-top:14px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Pursuant to Rule 13a-16 or 15d-16 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2"><B>under the Securities Exchange Act of 1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Dated July&nbsp;23, 2007 </B></FONT></P> <P
STYLE="margin-top:10px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Commission File Number 0-28564 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><HR WIDTH="17%" SIZE="1" NOSHADE
COLOR="#000000"> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="6"><B>QIAGEN N.V. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="1"><B>(Translation of registrant&#146;s name into English) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Spoorstraat 50 </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>5911 KJ Venlo </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>The Netherlands
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Address of principal executive office) </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Form 20-F
<FONT FACE="WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form 40-F </FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2"> </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____ </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____ </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Yes </FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT
FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No <FONT FACE="WINGDINGS">&#120;</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">If "Yes"
is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- ________. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">This Report on Form
6-K shall be deemed to be incorporated by reference into QIAGEN N.V.&#146;s Registration Statement on Form F-4 (Registration No.&nbsp;333-143791) filed with the Securities and Exchange Commission on June&nbsp;15, 2007, as amended, and shall be part
thereof from the date on which this Report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><HR SIZE="3" NOSHADE
COLOR="#000000" ALIGN="left">

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>QIAGEN N.V. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2">Form 6-K </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>TABLE OF CONTENTS </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-right:0px;margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Item</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Page</B></FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Other Information</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Signatures</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Exhibit Index</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>OTHER INFORMATION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">On July&nbsp;23, 2007, QIAGEN N.V. (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA) (&#147;QIAGEN&#148;) issued a press release announcing that, pursuant to its previously announced merger agreement with Digene
Corporation (Nasdaq: DIGE) (&#147;Digene&#148;), its offer to exchange cash and stock for all outstanding shares of Digene expired as scheduled at 11:59 p.m., New York City time, on Friday, July&nbsp;20, 2007. All conditions to the exchange offer
having been either satisfied or waived, QIAGEN announced its intent to accept all tendered shares, which preliminary tabulations indicate constitute well in excess of 90% of Digene&#146;s outstanding stock. The press release is furnished herewith as
Exhibit 99.1 and is incorporated by reference herein. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; margin-left:54%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">QIAGEN N.V. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px; margin-left:54%; text-indent:-2%"><FONT FACE="Times New Roman"
SIZE="2">By:&nbsp;&nbsp;<U>/s/&nbsp;&nbsp;Peer M. Schatz&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:54%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Peer M. Schatz </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:54%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief Executive Officer </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">Date: July&nbsp;23, 2007 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Exhibit&nbsp;No.</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Press Release dated July 23, 2007</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">3 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>PRESS RELEASE DATED JULY 23, 2007
<TEXT>
<HTML><HEAD>
<TITLE>Press Release dated July 23, 2007</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px">

<IMG SRC="g98707logo1.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>FOR IMMEDIATE RELEASE </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Contact Information:</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em"><FONT FACE="Times New Roman"
SIZE="2"><B>QIAGEN</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em"><FONT FACE="Times New Roman" SIZE="2">Investors:</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em"><FONT
FACE="Times New Roman" SIZE="2">Dr.&nbsp;Solveigh M&auml;hler</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em"><FONT FACE="Times New Roman" SIZE="2">Inside the US: (240) 686 2222</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em"><FONT FACE="Times New Roman" SIZE="2">International: +49 2103 29 11710</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em"><FONT FACE="Times New Roman" SIZE="2">Media:</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em"><FONT FACE="Times New Roman" SIZE="2">Dr.&nbsp;Thomas
Theuringer</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em"><FONT FACE="Times New Roman" SIZE="2">+49 2103 29 11826</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>QIAGEN EXCHANGE OFFER FOR DIGENE CORPORATION EXPIRED WITH </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>SIGNIFICANTLY OVER 90% OF SHARES TENDERED </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Venlo,
The Netherlands &#151; July&nbsp;23, 2007</B> &#150; QIAGEN N.V. (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA) today announced that its offer to exchange cash and stock for all outstanding shares of Digene Corporation (Nasdaq: DIGE) expired as
scheduled at 11:59 p.m., New York City time, on Friday, July&nbsp;20, 2007. All conditions of the exchange offer have either been satisfied or waived, and QIAGEN intends to accept all tendered shares. Preliminary tabulations indicate that the number
of shares tendered constituted well in excess of 90% of the outstanding stock. Accordingly, QIAGEN intends to complete its acquisition of Digene by effectuating a merger without the approval of the Digene stockholders, as permitted under Delaware
law, promptly after its acceptance of the shares. Pro-ration calculations will be announced when completed, and payment for the Digene shares will be made as soon as practicable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">As previously announced, QIAGEN received the vote of the necessary percentage of its shareholders in favor of the acquisition of Digene at QIAGEN&#146;s Extraordinary General Meeting of Shareholders held on Friday,
July&nbsp;20, 2007, in The Netherlands. Additionally, the antitrust waiting period required under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 expired at 11:59 pm EDT on July&nbsp;16, with respect to the previously announced merger of
the two companies. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>About QIAGEN </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">QIAGEN N.V., a
Netherlands holding company is the leading provider of innovative sample and assay technologies and products. QIAGEN&#146;s products are considered standards in areas such as pre-analytical sample preparation and assay solutions in research for life
sciences, applied testing and molecular diagnostics. QIAGEN has developed a comprehensive portfolio of more than 500 </FONT>
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">proprietary, consumable products and automated solutions for sample collection, nucleic acid and protein handling, separation, and purification and open and
target specific assays. The company&#146;s products are sold to academic research markets, to leading pharmaceutical and biotechnology companies, to applied testing customers (such as in forensics, veterinary, biodefense and industrial applications)
as well as to molecular diagnostics laboratories. QIAGEN employs more than 1,900 people worldwide. QIAGEN products are sold through a dedicated sales force and a global network of distributors in more than 40 countries. In this press release QIAGEN
is using the term molecular diagnostics. The use of this term is in reference to certain countries, such as the United States, limited to products subject to regulatory requirements. Current QIAGEN molecular diagnostics products are 34 EU CE IVD
assays, six EU CE IVD sample preparation products, one 510k PAX RNA product, nine China SFDA IVD assays and 98 general purpose reagents. Further information about QIAGEN can be found at www.qiagen.com. </FONT></P> <P
STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><U>Forward-Looking Statements </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">This communication contains certain
forward-looking statements including a statement concerning the month in which the parties expect to complete the transaction. These forward-looking statements are based on management&#146;s current expectations and estimates and involve risks and
uncertainties that could cause actual results or outcomes to differ materially from those contemplated by the forward-looking statements. Factors that could cause or contribute to such differences may include, but are not limited to the risk that
the conditions relating to the required minimum tender of Digene shares or regulatory clearance might not be satisfied in a timely manner or at all, risks relating to the integration of the technologies and businesses of QIAGEN and Digene,
unanticipated expenditures, changing relationships with customers, suppliers and strategic partners, conditions of the economy and other factors described in the most recent reports on Form 20-F, Form 6-K and other periodic reports filed with or
furnished to the Securities and Exchange Commission by QIAGEN and the most recent reports on Form 10-K, Form 10-Q, Form 8-K and other periodic reports filed by Digene with the Securities and Exchange Commission. </FONT></P> <P
STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><U>Additional Information </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">This announcement is neither an offer to
purchase nor a solicitation of an offer to sell shares of Digene. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">QIAGEN has filed a Registration Statement on Form F-4, as amended, and a Schedule TO, as
amended, and Digene has filed a Solicitation/Recommendation Statement on Schedule 14D-9, as amended, with the Securities and Exchange Commission in connection with the transaction. QIAGEN and Digene have commenced an exchange offer and mailed a
Prospectus, which is part of the Registration Statement on Form F-4, the Solicitation/Recommendation Statement on Schedule 14D-9 and related exchange offer materials, including a letter of election and transmittal, to shareholders of Digene. These
documents contain important information about the transaction and should be read before any decision is made with respect to the exchange offer. Investors and stockholders may obtain free copies of these documents through the website maintained by
the Securities and Exchange Commission at www.sec.gov. Free copies of these documents may also be obtained from QIAGEN, by directing a request to QIAGEN&#146;s IR department at QIAGEN Strasse 1, 40724 Hilden, Germany, or from Digene, by directing a
request to Digene at 1201 Clopper Road, Gaithersburg, MD, 20878. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In addition to the Registration Statement on Form F-4, as amended, the Schedule TO, as
amended, Prospectus, Solicitation/Recommendation Statement on Schedule 14D-9, as amended, and related exchange offer materials, both QIAGEN and Digene file or furnish annual, quarterly and special reports, proxy statements and other information with
the Securities and Exchange Commission. You may read and copy any reports, statements or other information filed or furnished by QIAGEN or Digene at the Securities and Exchange Commission&#146;s Public Reference Room at Station Place, 100 F Street,
N.E., Washington, D.C. 20549. You can request copies of these documents by writing to the Securities and Exchange Commission and paying a fee for the copying cost. Please call the Securities and Exchange Commission at 1-800-SEC-0330 for more
information about the operation of the Public Reference Room. QIAGEN&#146;s and Digene&#146;s SEC filings are also available to the public at the Securities and Exchange Commission&#146;s web site at http://www.sec.gov, or at their web sites at
www.qiagen.com or www.digene.com. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"># # # </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g98707logo1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g98707logo1.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`5P!U`P$1``(1`0,1`?_$`*\```("`@,!`0$`````
M``````@)!PH#!@($!0$`"P$``@(#`0$!````````````!P@$!@(#!0D``1``
M``8!`P,#`P($!`4%`````0(#!`4&!Q$2"``A"3$3%$$B%5$687$R(T(D%PJ!
ML3,F&)&A8E-$$0`!`P($!`,%!@4#!`,!```!$0(#!`4`(1(&,4$3!U%A"'&!
M(C(4D:&Q0B,5P=%2%@GA8B3P\3,7<H*2)?_:``P#`0`"$0,1`#\`O\=?8^QY
MDG*QT0W4>2CUI'M2"4#+O7"+9'4=-`WK'(77^&NO6R""6K>88F.<1X`G\,1J
MFIAI&=65[6@^)QXL1>:9/+_%A[-!R+H/_P`[60;*+".N@[4@4WG[_H`];);9
M50@NDB>&CCD?OQA%<:21`R5A<?/&RBH4I]G?=IJ``4-3?R$1TZYQE@:_1I.O
M$X1RN;JU#1C79>\5"OK`VF[+#1CD1#_+/)!NDX#4`$-R.\5":@.O<`[==*GH
M:VJ&JFA>YOD#B%/74=*=-1*QKO,X]:.F8J8:E>Q,BSDFA^Q7+!PB[1$=1#3>
MB<X`.O6BHAFI2E3&]I\P1^*8VP3P50U4TC7#R*X[*KM!NDHNX5(@BB7>JJN<
MB*:9`[B8ZAS@0I0#ZB/6J']=P;"QQ>>&6-DI;`W7,]H9XG+&JM<C4-\[^`TM
M]>7=B.T$$Y5F)C&UTVD-[H$.;7MV$>I\EMN,;.I)!(&>P_RQ"9<[?*[IQS1E
M_MQMHJD[:CV'3:(@`@(&TT$H@(]AZY;Y86NT2`AV.@UDCAJ801CQYJRUVNI%
M5G)J+B2GT`@OWB#8QA[_`-!%#@<_8/H`]38**6?XXHW%OD,OY8B5%93P#3+(
MQK_,XXPUFKMB(H>"FHR5*0"F.+!XW<&*!M=!.1,XJ$#4/J`=95%)4T+-<L3V
M@^((^_AC\CK*6L;HBD:2/`_PQ[ASE``$P``:".HB````&HB(_H`=1BYP>(XP
MI.)",<SJR9-`QIKC(E"9O#,'=L@&[P#;1;JR;0#@8!VZ#_<$I!U'T$0'J<;-
M7%O7=#(AYH?XX@LN]O+C$V5@(*<<;@@Y;N$R*MU4UT5`W)K(G(JBH737<11,
MQB&#^0]0]#HR6.:6D<CB>V1DC=3'!P\L=C7MK]/7K[&6,)CB&@:B&IA#4``1
M[=_T'K`!TK7:"A!QA)*V)S0X*"#A7^5;I+7*XS2SYRL:/CY)ZPB(\R@_'9M6
M;@[<IRHEVD!TO[0F4.("?4VW70`#I@=MVJFM=OB=$UOU+F`N<BJ3GS7V8`FX
MKG472OE$KG=`/(:U40#+DGAB-TS'14(NB<Z2Z1RJ(KIG,1=!1,P'(=!4H@HD
M<I@]2B`]6$113ET4K&$/XY#'$:Z2("6-S@YG#,_SP9C;+]A_T*<3P+">SMI4
M*FG)&V%$PK"0Z<EJ)=ORB1YA$.W=4H?4>A*_:E++N]M(`!3EA>GO0C[?Y8*/
M]RSP;4-2"?J6N#5]N`W<*JKN5G2ZJB[M8YU7+I8YE7"ZQQ,*BBJZ@F44%0VH
MZB(ZAT78J6.RGH4K6!FC^D'EY@G`EEJ7WMO6JW/+B_\`J(Y^1&-ZQM=)>EVF
M(=QSA4&KEZU:23$HZMWC%RZ117`Z.@@*J15=R9@T$I@]>X]<._VB&]4TIE#0
M]L6H%`$<.>2?RQV;%=9;/41,B+M!ETG,E1X9KB5N1]VE7]L/4$7*J4+#M62R
MK8AM@/'SQ$5SJNM``54T$U"%3+KH!M1TUZK.Q['%%;&7-^ET[Y"%('`%$3AY
M\,6/>=[?/<7V]FH0-C5%/$CCXX&<$R!MU*&T-?MTU``_Q;2^@"/1%ED-8/II
M`SIEY'RM&67-,#^*)M$34QE_4#`?F<<\_/!AX/R9+MZ?<V4LHM)EI\+^8ASK
MJ&75*W]E;='JJFU."**R9?;W"([!'3L'0HWEM.EIKM3?3AK62R:2GN*Y^_!1
MVENRIJ;54&H+G.BC4?:F!3G9J3LDFZF)IV=_(.U!4475$P^V&HB5!L`_]!ND
M!M"E+H&G1(I*"EM]$RGAC8&D!<@>&>![55M17UCYYGO*'+,C\,8XF9E*_(-Y
M>$>+Q\DR,59!=$XE!42ZZH+ZZE40/_B(8!*8/4.W7U;2T]PAZ%6QKXTX(!^"
M'&REJJBCDZE.]S7+XD_BN"TS=D^7<4FCM(U12-"[0GY66,W4%)<R)4&P&C4%
M@#4B*[A4^\=0U(4`]!Z&NTMO4@N=;+7-$K:-R`9A2J+D0N"+NR_U?[91143C
M$:QJDH#DBIF#@.C%(/;:`!H`;0'4H>GV]AVF`H]NBH[_`,8A<&Z`,@@X<?!>
M>!@T?&9@7=0G,J>(R\<$EQPNDE&6MO3U':JL)-I.P08GWJ$8R"*2CM)PUW;@
M136(BH50H:%UT'H?[WLE,^VFZ1-:V:(AN62@GP]^+ULN^5,=W;:Y7.=!*-2<
M<^''C]^#[^[3U[[?T#UT]?33H/Y+IYX,6>O_`&^&/QB:@.AA*.NNN@#^GZ]O
MIU@YA+2&E"2N,@B@D*@3`,9=P184I^3L-/8C,1DHY5?.(MGM+(Q[QR;W7`)-
MS#_FVJRAC&`2#O*8P@(:=%C:V\J*2)ELN#VQ31!"]RH>8Y>!`\,"7<NTJYE3
M)7T+#+!(Y0U@S&6:CVKPQ$</A_),R^(R2J<HQ*)@]Q],(&BF3<FX"G,J=UH<
MXE#N`)@8QOH'5JFW;8*-CY'SM=I"#3F23X<O><5VW[7O=?)TG0NC!(S/`#GJ
M\#X`8-)+#<27%@XZ,X*!SE^>M*D2U_[A!4'!9$$Q,`B1-8`*`"(:D#H2S;CG
M;??WH*&`II_V>W[_`&X*G[!3NLO[,$>\A2X<-0X8#*<P[D:#>J-%*O*2293G
M*B]AVQY-FY+W$JA%&P'.B4XCKH<H"773Z=%VEW;MZX1B=M4U2Q"'Y$%$]AP*
MZ_:5VMS"R&%[I54:4TE,^(Q*&)L#V5W.1M@N$>:#B(Q=%^G'O!($F^=-E06;
M)G0(H86S0JI`,??H8V@!IZ]5K<V\*`4[Z:TR&2ID9IR^4#Q7F<=W;&T*U^BK
MN[!$UC]2',GRSY8D;..%Y6W/R6ZK%0<2H-T6DI%F.1(SY)K[H-7+-4YRI`Z2
M35$IBF$`.4/U`.J]L[<T=MA%ONSG,AUZ@X9A?`CP\\=S=NVI;C(;A:6L?,6:
M2WAY*#_#`LM,69'<O"LPI=A27W"&Y5@=%L70=`$[U40:%#MW$#"&GZ]$N;<N
MWHX?J151ANHD@$:N7+C@?TFV;S,\PSPR`II&667MP9N)</(TRLS#&?,W>2EJ
M;_$FBHB*B#>.]A5%.,27UT6,D5<PF/H&IA[=@#H3;BW.+U<65-"]QIH7*PE,
MSEGY#+^>"AM_;4-HM[Z:L:!),U#P08%RXX*O-:D%DHJ)=V6'%31C(1*?R5BH
M:&V)/6!!^4DX2*`%[%$AO4#?3HAVW>=FJ:%K9Y.G5,`U-=]B@\_Q3EBAW?9M
MSMTSYHF&5CODT9@Y_F\,E]^/E0P3>K,]33DXIU6HDJB8O)&72^*J9N/_`%",
MF*@@X5<G#L7=M('U'K"];SM%JI^K#*R>0CY6DDCVH,:[3M&\W!_ZT9B8O$X*
MG+.(4+C586-KYTF4M4VY6\(1<PD1<,@;HH*,%U.^PRA6Y#%.("`'#OV$1Z'.
MV=UFRW622Y-<^DJ/F/$*>!^W_3!%W/M?]UMC(Z0Z)X/D(3@`B8"M?%F26S@6
MRU*L!UP.)`^)'G=-SZ'V@<':`BUVB'UU_CT6X]R6)\?4?51CR7/V(<"8V&]!
MX@;3OZO`E/A7R."CP7AF6JDF:VVQ%%I)E:+MHF-*L1PNP([`I73EVHD)D2.3
MID`A2%$V@"(B(#VZ&^\-V4U>P4%&X_3<2XKF0>0YCSP0]I[6J[;5"NN#6]=$
M:!F@YD^>"IU-I_'33U[Z>FO\^J#U&HJ_!X^>"(C.HJY^&,@F[`(!]?KZ^G?3
MN&@Z=?KGM;QQBN:>:8KO\V?(?E"3R19\982LJ]%I=.E'E>D[+!^V6RVJ9C5Q
M:2BB,N9-16)AFSE(R29&^U582"8QP`2@#6]N.TEDCMD%ZW)"*FKG9KZ3LF,!
M^4>9+4)*9*@X*5MWOW0NTEPGM5DD-/20OTB0!7.(".R7+XE`SX9X"NB<T.3^
M/)UO.Q&8KC,^VX(J[AK?+.;3!2J6_<JU>L)8R^Q-8NI=Z!D5D]=2FUZ(=S[:
M[*N]/)0.H(:<O'PRL^9B9)P'$GQP/*#?F[+14BN^LDF@;G(QP^8+[3A]D=SO
MJKGAROR><0I4Y9D8U7>4M)U]A\E`NG'D@D71]5`C7"ZQ'0*]S@RU'N8.E?J.
MV-?%OQVRF/Z@^8//#I("3[1\J>*'AAD*;N!0R;-&Z8V:(W(U.?4.04>'-5PA
MC(7-7DYDJ;<34GEZW0**K@ZC6`I4L\J4#%H"("DV:-8M5)98B(%``.NHLJ?^
MH3:CTTMM[9["M-O;1T]OCGDC0222\5X$@H5^["ZW/?NZ;G5&N-;+$-2-:T?"
M<\AQ"`\^."ZX9^1#*U:R+6<?9EM#R^X_MTLQKR,[8%$5;+4I.4<IM(QZ$L9,
MJ\E"F=JE3<).#**)E,!R&U`2FH/<OM#876B6Y[:8ZGN,,9>6`#2YH'(>/@<O
M`Y8NFQNYUY9<HK9?7":GE?H!Y@_RP5'D1YT73#EC3PCAUXC#V\(EE,W2Z&1;
M/'D&UF"*FBH:#;.$5FR,JY;%]]5RH4PHIF)[9=QA,%`[.=L*3<%)^^[H>Z6@
M$A8QH'S$'B0O#DGM/ABV]SNX5PL-6VR[?#(ZPL#GN)R"A4&7'"?(WECR9B9D
M)]CG;)@R)%RN1^=9Y"28KG*'=->+?*+QBB)M1^P41+W'0`Z8B3M_L.2%U));
M(?IUTZP!K!/D@3[<!<;QW6V=M1]?,*AH#M`'P_:O\,/EX6<XD<V8BO\`.92%
MC%W'#<4,O=GT<F1I'3E8^&\>-K2R9"<?A+KA'+(N$`'VB+E`2"!3[05ON+VS
M.U=PP6VTJ:"M>D.>;7%%:3[UYY98879G<".^6.>IN/Q55)&'29(",P$XYJ,)
M_P`[^0GD+F.R2#FO72<QA12N%@@*I379H9T5B"I_C.9^;:B$I)R;A#:90`43
M03-J!2:='O;/:/:^W:,P5\#*^Z.`UODX,/'X1GQ1.7'`4W%W)W%N*K?^WU#Z
M.V0E`UH4NY!<POVXPX.\@W(?$%CCG4]=9K)M(%P@2P52Y/E)APK'`H4'*\),
MNRJ2,9*((")TM%#HJ&*!3D[Z];MS]I]HWVET4-,RAK`"0^/-2F6H(%'EC]L'
M<S<MF>!-.ZHB7/5X<_9AQG,SG$TPMA[']EQ<FQE[?FB)),45Y*H"LRAJX9BQ
M>N[&_8E5(#MTV))(I(-S'`AG!A]P=I#`*^=ONVTNYMP3VR]?IT=!)IE#<U<"
M1I:<LE''++A@X[Q[@16BS4]1;R725S%B4<D7//+[\(3D^6/)B9F#SLAG?)H2
M!E!7(6/L[Z*8H',;>8B$9&F:1J28&[%(".P`_ATT3.W>QF0?1&VPB,!-:`O/
MF[+C[\+J_?>[))?J6UCP25T#Y1GP!_TPW_QW\[[IERSFPAF5ZC-6=6*=2=*N
M7LMF<C.DB$A<2<).(M2-VB\FBP+[Z+A-,@JE(<#@)@W"`.[G:ZV[>MPW!90?
MVX'3(P\6N*H6#PX`A?=@V=M>X51?*LV6ZDNN!^)CD^'2!FI5554R]^'':CMU
MT^FNOUTTU]/37MTO&C_B?[>/FF#7\'53/5P\L<#B;;J"9Q$1`1#01["/<.P#
MWT_].M\K-8,8X-`*^*$'&L#]3IGY23GRX'%2/F3@"Y8&S7=D+!&OQJEJLT[9
M*9:SME/Q,S&SDBYDTV@OPU12EHU1V*"Z!A`^\@'#4APZ??MWN:BW3MNF?3/8
M:^*!K)8@?BC+!I&H<0'``@\"OMPEF^+'5;<OU1'5M>VDDF<Z.1P1KPXZOA/`
MH2A\","JR:NI%XVCHYLYD)%ZNFU91[!!5X^>.5C%(DW:M&Y5%UUE#&`"E*41
M'7J]2]"*BEJJM[8J:,:B]Q#6A"N9.*S3Q25#W0TS'2U3F%H8T*XJF8`P]F-X
M09,'QSOL:*-%&^5Y"X)9J2JBRA2JIO&94F[2G*&U*FC)K5M'02;A`KT^P?KH
MJ[NYE`WO`;T"PVX1?3B3\I:Y`YX/,-(S/!"O#!_I]A58[:-M+]3:E[VS%A4%
MI:J-(\2O#"*I)D^B)!W$S#)[%2T:L=G(1DHU4CI%BZ0'8LW>,5RD5:KD4`=2
M"';T[]-/2&"L8^&E>V2DF^-LC2"TMXDAW!`.>%ZGIYX3]'.QS'QR!%!!*'!%
M\3L#7'D!EZJP5:C7)Z[#SL3-72SE04&,K\)$R#=XY*J^*44/R+X4/9;H%'W3
MJF`VFTAAZIG<;==#MRP5,U6YC:F6$PQQD@.>O!S1S'GPQ;MD[<K[Y?*:2&-_
M3CFU/*%&CQ/A@R/*;@6Y0>87V=6$6^DL?WF,@FTI*MD5W"5:L<'&(PXL9C84
MP,6DBP9)+-EC:)"<%""(&TU'G9'=-'-8O[9D<P7&GE,C&*`Z0$ZOA',\B.(]
MA&+SW?VK6PW_`/>XV/=1&$*X`EH('!>'LPI[W$P`#`H00';M$IP,`[NY1`2;
MA'=]--?X='H)&^4RY=='9_E/,>1&2X"[GN$NMH+I3&&AO/)<T]^'B^/GB);Y
M#"&?9RY-7M3+GJA+4&G,9!)PT>DA#M9,_P"Y7K)9(%VS)Y(O4@;@8H'402,I
MIH<.E@[O[]HF;EMM)0Z*@6ZH#W.80X*=(+5']('Q>!PP';;9%2[;]=)4ET9K
MX&L`(1$<7<_,IA..1,=W/$UMEZ+D*#>UVS0KE1LZ;/D#H(NRD,<J<A%KG*"+
M^+>D*"B"R1C$,F8.^O3%V"Z4.XZ"6^6Z5DT4H:NDKH\G#D>1!S'/`1NUKKK!
M7R6ROBDA:''07@@29_E)^;QRQCQ_C^XY4M<51\?P;RQV697*V;,V")URM0.8
M`.^DUB`*,='MBCO475$"$(`B/TZ_;G<Z"S4+KE<Y60T;`?B<4"CD/$G@`,R<
MAC706ZNNE6*&WQ2351_*P$N3Q]@\<.4Y]<0+?&X%P#)TID_MIL!47]D7%E%M
ME';X\2JUC'"]ECVA-5G#1E*L%??(4!,1NH4WH4>ER[2[_H)=X72.Z%E)#<ZD
MR,?(=(742&@G+-0GC@[]P-D5\.W;7)0-DJ'VV+0YK!J*:<W%.0S4^\X1P)R?
M_8GV`-WW`7:82@82F*80,4Q=>X#W#Z]-`[J2NUEI!=P'EP!]XSPN[`R)NAK@
MYH)S'B2J>[AAJ_BTP%<[)F:/SF]BGD=CV@Q\XG'3#MNL@C8;/+1KB'09PV\A
M1D$(YL[54<*DU3(;80!$QM``'?/=UOI-NG;S)(WUDKP]S002T-.9=X*B#Q]@
M.#5V?VU5U%\_?'L>RFB:6AQ!`<2%R.+'N[^/;7T^FFGI_+I3-;.CU/R:5PRZ
MG41SUC^.,AQ,`:E#</T#737L/;7T#7K/&S"#_*;YBL,\3YUW@"L8TK'(S+B2
M+9S<:S:G"9<<4$';=)U&MK,N6/D5)6QN6Y_<_'MO;4;)F*991,3$*+$]G>R&
MX-\1C<$]5-:[(0[I3,!U3:7%KM.8"-<TM*JI&7`X7;N]WPL>RJG^WX:2&XW:
M-.K&_A%J:'-7(YEK@>61XX4UQK\^4'0\A1CS)?"G`U7J<A(HH35IP;&.X.[U
MN-<K^VYE6;&9)*$G_@HJ"<[=)PT55*40*(#H'1FW;Z;*VXV4QVK<E;55\;"Y
ML,ZM#W#@UH"*OO'C@/;3]1ULH;P&7:RTE-13/`,L2$M]IS3[L6U&/)7!TC@(
MO)YMD6OFP0K337\<A'<BG#IUA-L*ZSA4#E*X1?(J`+<[02@Y!V'L;/=^WI)Y
M=J[@CW`=KSP2?W"^7I"(9.:?+V@ARC),^&''9N6P_L0W+2U+?V71K+T4>Q/N
M]N*FG*/SZUJ]Y&D0Q;PUP=<:C&/7#>'NF>8IY+7&T,$E`2;RXQ\06)4KZ#H"
M`8K9=PZ73+H4^@@(=.ILSTXW.T6)C[Q?[E0W`@:HX6ES0#RS5<B040'V83O=
MOJ4I:VZ2MM5HI*FWQDCJ2?,>2^T\1[>.&?>+[S)X8Y-65AQYNN+*AQPRK*%U
MHT5452%QQD%VBW,N^BX0QF$>XA;21%,5$VCD5CNR%-[2AC$VB'.[W8F^[4@?
MNJEJ)KO:&YO?(O4C/]1:3D/8`GLP4^T??3;V\IFV*6E9;;G^01YM?Y<%7[<&
M+Y)?)9A?@+18]G;(-#)^5;\Q=!2L.(N&[89>+05^*^G[6^<-I%"%J#94WMBH
MJBH=TJ`II%,8#"6E=J>U=^[I5QJK<V2DML#AU:@G26<](0@EW/+ADO$8('=/
MNA8.W5O$ER8*FX2CX(<OB'B05R\N/'%:^I>=][7KXE:9/@3Q/",&2.LJVK$7
M)1%L31$VXHQMC?-)*+*_33[@88],AS=_L[=-S5^G%];:WP1;GNTLC(T:US':
M2[P7(D<,UX84ZE]2O3N0K6V.B%+K4G\S0?Y<O/%MSA]S&PQS2PO'9HQ%,&_'
M`)HRXUN6$K6Q8_L[-L1S)URS-QV$1.T1,"B+DNK=VU$JR1A(;LCF[]D7[8]\
M?MV]-D%3J+HY"IZ@)R+5SS"9<0<CAU-H[VLF^;$R^6Z4-HVL61B)TT&8)^W[
M#A`/D"\\>(F60)C%6#./^*N1<73WCJ*D<HY=26?5![--%3HR#&BPK)HE*2,6
MT63$OY`7B#=R8!%,IB@!S,WVO].=_J+4+[N*[5%EDG`+88EZA:B@EN8*Y<`H
MY\,+KW+]0NWJ:X.LM@M\%T$91TDB!C2#F02F2A,SCJ>/[SQXI>9"A\6YUX\X
MIXZ0UO=-(=GE+$*"[.JL99T<K6,0O,*\9KRC&'=.50(+\KQ=)H(@98I4]3AI
M[C^G._P6DW:P7.KO%5&23!('!Q;XM'!4Y)GP&>/NW7J(V_/=6VV_4%):X7!!
M/&01JY`D!4]F+"W+SF+AKA?A65S5EZ8*$,3VXZJ0$2)'D_?K,^:K.(JMUEL&
MJ;E9\FG[BBYA!LU;`9=4P)E[K7LK9.XM][@BL%C875!*O<A2-H.;G'D!X<2<
MAAC]Z[SLNR+#)>[P_P#00AC,ED<F31[?'EBHI<_/"\L-_7M$?P&XFA#E?*.$
M4[4PDIRWN406!4AWUACV\7%_DCD+W.5BH4#CVW:=W<I/3A56^W_35&Z+DQI8
MAZ32Z->87,HN7'"85OJ.TUK:VFV]0-!=^9-3@N1<U`0?=BR=XT_)GA?GS2)*
M-J\$CBW*]#:(*6[#IW:#H(V'55%LTL=4?(LXUO,U5TX+[8F(@FJT5,":Q0$2
MB93>YW:C</;>M$E?JJK14N/3G)77FB.4DM<F:'CFF&?[8]T+)W&H=-,&TMWB
MR?"/RY*2/'P\<-)U+V#MW`1`?KVTU_X]^A.CM>E`@'#R/_;!:T,T\<U1?/&,
M=!T]?M.`A]VGH4W?N/?0!Z^#0W7*"3KTY>&?W8Q:006G+02GGD<?S!>8T'?:
M]RRY+Q&3"ORWEMF_(Z]B&3!47+E21M,E)QCXHJ%#>Q?0[ANLV,'V&;F)L[:=
M>OW;N2EJ]BVZ>QR1.M[**)&M`0$-&O(9`Z]1/B57-<>2/<:*KIM[W"&]LD%:
M:EZN<22A*MXY_*0`/#RP-Q1#OH/W"4H^@Z`('*`#J`"`?U#W'3MKU;&")PZF
M7U3VH#X9@E/#ARQ37:VDQ(M.QRD>)0@8L'P=0S>;_;J6MZFA/?LX_*!"[(M0
M2<`H;!Z,Y&LY1^1,0'W*M_J&F+TYR![7M%.H/V`(]*A673:K?4VZHJ)(D_;7
M1EWPIUR&H`?Z](.?%$PUU-;]S.]-CH(HY-0N`>`-2F)'*?'2':?+%?`#!J;4
MN@;M0#0H:E$PCH&W4```'3]>W38QEC7@ZBZ%-69)4#/"I2F5SHV\)2T@CAGF
M`HQ-G&R#O%BY&X$@\9D?JW]]F#'9*>,:54[Y&9;VJ+?I.2%2]&[%NT477,.A
M2H)G$P@77JM;MJ+33;.N-1?'L99Q0S`:DS>X9#/B?#PQ:]A0W.LW50-M+7_N
MAJFKIR^%I&>7WX9QY^X:\1WDBO$E;"/?P=@QWC-WCITNFH5BM4V%:0C9%",.
M;[#@RN"4C\@"_P!*JP;NYBZB#TQ5=G?VI@HZ1S?W.&JFZK1\VESW%I=S*-(1
M>28+GJ7IKNS?]14U0<;>Z&$QN*EJM8U0WD%<"H'OPEH=`UTT[$`-?0/7]?TZ
M8)@Z5$YD;BB`<3YX71TKI'-D<$U/<?P_EEBPKX6:?G*<XW>4I?&'YM)C-<>%
MJK5CLRF*F]RZ-;N:[1"%$H`FM/-:X[`J@I_>'RFX&$-2]*KZ@Z[:S=T[6@J9
M(W5<5QU3%R$B/]--1*G3J\<N.&O]/U)N-^UMR3PLD-)+;],2*A?\2AH\=)/#
MRQ7E3T*FFB9,Z0E`""11,2&2.@)T545"F`/;5253$IB#H8!#TZ:ICZ2KD?*H
M?$X-=$1P``.0\![,*M,VIII7L<"V5I+9`>))<#F#CDH`BB<`(<Q3%.F!$BG.
M=43%T]HA4P$YCJ"(%*`!J8P@`:CU^@SBF?5/>V.G:N?#(8^;'%]2V"-A?4$C
MW$G+%A;S,4W/,!Q/\5SC*032C&#P*I5K:+L'"I([*BM9I3ILTG`$NB,ZI5&"
MB)15T4.9LN7U`_2I]B[EM*HWKN_]L?''45%R=)3(C28NHXHTA/AS^49(F6&G
M[[6_=4.P]L-N#97MBM[&3J24E`;F[_<B9G/%>@V@[A,`::"(@.FF@!]/H/;T
MT]?ITU<QD:\L>?:!PX>'#"M:@\A[5X<RI^WCAR_@3A;Q*>2'&K^G`]&)KU*R
M0_R*NW34.R2I3RN.(Q%O)G+_`&TRR-H78`V*IIN63W%`1(.B_>I.JL[.UU11
M5K@+E+-&(6_FR<TDM\$0J1R7!\].-+=I.X\%71-<:&-KNJ0J9M(SY$H>>+_>
M@>OU`G_/Z_\`MUYF\(>HN9_`9?Q&/2/(S:>0_$\/P.,ADTQ``-V#7M]PAW$!
M+ZZ^H@/4O2$+>3@A]F,=()7P*^_"C_(]XT.%G*IFMEW.-A2P3=H2/;1KC.D3
M8(&KF7C&I!^!'7).R_\`;]D;,B;RMO?V.TRF,1-4"B!>BMV[[S[M[;-=1VR2
M*:T)G#*1I;XH[YFYE2A0\4P.]S^G^T]Y[JRBHZ"OJ-TS/`9]%&Z6:3(#_P`8
M:]I&0!=I4`'/"/L(^.WPP5_(\<CDWR$M<U)-)-,K>CNW<=C:H3"R:P&393EF
M9M%!?L%0T!0&T@T(H7_'M-IT0+OZOK[<J)UOL\5OHJD9&5K^J0O%`]6A?:<6
M:B_Q7]XK)#^_7O:FY:JE;\>D0Z6EHS7X#K4<T"KDF+:D;!X>'#[>NQ$?1EL(
M)4I:$1BX\8AUCDN/4(<[1PS*5LHK!J5I.&*8J@`)DO:U$1]1Z71]RK'W!U[D
MJ2ZL<_JF4NSUJJ@^U3X8[;=KNIV,V;-02P2M2F%(Z-PD^)&],,347$D`'YE/
M%3BN'/>#?QU<GKI9)7B-RS&MM6RI)6>Q_CRP4O,$!5VTLNI\/\8!I`LW7XM5
M1%0C9-PY<I%`NP@Z%T!D=K>K#=E';HXIH**XOA`;U"[02!P#@S(Y#CSS*8#G
M<_T)739U737'<]LW!MUE5([IMJZ69C9$5SNF96-)0<U("C!T<8.`7CR\6=@C
M;K;LJ5[_`%HL$;(LZ]DO/%RJE>ETXTA4&\ZEC^O**1D7#-E@<$(Y<)%7=B0X
M)BOM$2B/NYO?'=&^Z(6^[/IZ.PZR_H,*`N_W/^=R9?"H`\,7WL;Z3KDP5%X[
M:V.^;BN5*=$TU/2SU'2ZF;5;"QS6DH4)"Y'/!7\E.)O$;R88C@BW$\5D""9C
M).<;Y=QM8H]6;KSQ57\?)N*K:6`2$>[:*N6GM.FBY'#10Z7WI[R@(5OM_P!Q
M]S[`KG7+;4\+X*A@;*S)['LXH05TD#@YI#@N-O=7LS'<IY=E]R[=76^^T:-,
M<L;X*F(O:',D,;@"B.#M+VEOB,(KO_@@X'<=)!O:N1O.JRU.@.'`JL:U/IT*
MHV2::E4'5HUD=7\C(B0/L4.RC1/]?M$0T.=1ZM]Q0T1H106ZFJ"U-;YG$KR=
MI<Y#[,"?MYZ#[EW'NK*79U->[[TD/3I:<DD+GU'ANE@.2Y@CEAQ?$#DUXP,;
MU"L\>>+F:</UB"B5#)0]:5G'<#)3TN_.0'<N]E+@C&*V6QS#G:998ZJJZQQ`
MH:!M*"P;CWG+NV[R72^5S)+K,44.:`@*AK6M0-`Y)ATG^C_O;VBVP7R[+NU)
MMBE&ISA&^8,!^9TSP9#PXDH!Y8#3G[X<O'U?K$_SA9,O(<.;!>9\X2\VE,5=
MECFTVB137?N'2=:M2["/93LH@U574!@[;D6$IU#)";<83EL_U([RV';8[?<&
MP5UL8W0WJG26M0H#(T:B!D`N>0"X52?T>0=Y]RS0;#MUXJ-Q-89YX+?!)4NT
MJ`7.B#7N8`YP^5`O+$+\3/'?X@>-=WALGW3F/B_D%=:L[0E:PG><EXVAZ1!2
M[/\`N-9<*A$2:R4I(LEP!5`SYRX124*4X);B@;J+O'U/[EWA;G6>@EHZ"C?D
MYK)%<X'B-;D<T$999Y\1B_;/_P`<G<S:]P-SJMF;NN%:JQB:V5<;6$>3(FZO
M_MEY8<WR)L'!KD)1"X%Y!9'PE9ZYD^*@9B$JL_D2MQ4O+(38ZTZUU);\NUE6
M[UTJJ!XN09B!E##_`&S&`1`0_9-T5.T;S3W6SU/0NC"`S@[4O(M*Z@>8/'%_
MO/8/N%OBQ5T%7M2]UMBHWRQ5A91U.F":%>JQ\C&+&Z,M=J"A$*C"9[/_`+:?
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M`&GF1&-*E<,CVIZZ?3^GU^F@AMTUU[!U1N@-`;R`(]Q()_`8R`_5+N:AR^XI
M_''PZP")"Z:")AU]-2B40UTU`?H/KULTN4`\QCYTFA-016:OO`_CBF9E!_E'
MS#^2F=P,ZN\E4\$8SL%S:Q,4T$KR,K='QN^0@I^ULH98Z;"6O%SF^R+AR53X
M952$#:0A@4%LS';KW#)02N/[:QW`9$`!"21Q)/-,LARQ[[[0HME^@'TB4W=U
MMMCKN\%XI8'-DD9G))6-ZT36/0ED,$$C%8TGJ:7.^%SB`WZQ>!+@5*T9>M0D
M=DJMV7X`I,\A(WR3E9A"1,D&V2=PD@*E8>I*+!N4;%:H)F`1*42#H(6:39%A
M?']'%"8].6H..HKF%R0I[!A%K=_D]]4U'N']\N-9;:NUB74^B=2QMB#&_,T%
MKB]I<.9+O$@\,)WX8Y2S)P:Y,Y^\>>1;$YLF.K/7<OTAC&^ZLK$Q-P3QU*V6
MH7JJM7*RQX1G;X;VTWC,@E1$[DAM-Z0F-5[4^MV_<*G;U01);RUVDDGFU00/
M/F,.UZE=A[%]1?9+;/JXVE;XZ/=\<U#52",,8)*9E0V*I$H;F712J&'B-"<"
M1B:/]MDF4M_Y0G]LB(&Q[BXYP,!$Q#?-V4_WG``#:&W0?IUTM@M#8ZL%"QLH
M`]GQ+]F*Q_EV<10;,:]SW3=2H74XN0"-H:@0(7>'(X&+F#*77RH>2NQXOQ.Z
M2?5FC1=LHM`>ND%'<0QK>,8N7E[59#[?L*G:KLF=LBIJ`J`JV`!'0`ZYMREJ
M-QWR6BHPPPQ`IS#B.)]^"[Z>*?:WH@]'U/OC?C##?[[5TTU0QZ-D<ZJDT0P.
MYAL,(,A=R"A!QP27A7YOM\&XEY3X5R#J".)*5>.0E$@72BB#HZ]8CE4\ATID
M42E*W43E&K1P*90*)!6<'T'0>NCM6YU-*:VVSZ0:9A>,@/\`Y-X\B@_E@,?Y
M&_3R.XN^=G]S=C@FFW-54UKJ)V#5KCF+?HJDN!0#I$1`<"C?B4Y0AP/XE6OR
M[9ZRWR'Y49`L;NF5B7C4+`UAG8-I27E)U$\G#4"L.W'R$:?2ZY#H@"AFJ8.!
M,*0`('.HIUR[797;OJC=KIE$'$9#BG!H\`U?#V8*?J9[Y6OT`]OK!VB[(V^F
MCW?64[B7O:U[6-C:P2U,S`0Z269Y`^)P"@DDHA8?R6\-OCE4@)&I8_S?7^/6
M7(AL@NR/=\NQ5ACA743!PT3ME2MDVA,-V;U$2F!PU5;+@`@<FH=ALM=M;;,S
M7T\!;#6HT`ZN'CD3F3X`C"F]I_\`(#ZPV5,>X+Y8JS=.QI72"5L%LF9`]KOA
M>&R0QOC>8R"T-<UV8S(4D"[Y.*16<4>-K`F%&/*".Y4RM#S]&*+6L)^K3,E!
M0S^BW@(^!]J%DYQ\$!&'3638&?+JN12#8900(4H<O=,<-/MZ*-LPJ3%(&%9!
MX'\H7@B9^/'!L]%-\NV\?5WNC?\`<=G3[*HKIMEY;1F*>*.9\5=0ZG@2PPZB
M]I=(\,:`US1QU$X&WC'4O"6]P#CQQRCL^0V6=58B1-D9E".\H)1;61"9EB-$
M&:=?B%H<J`0I6P_Y<PAN,/UZYE-%LJ:B8ZO88ZA,TU'-<B"`GNP8^]M\_P`C
M%O[LWJF[/6RCG[=F:-E#*^.C!>TP1/<O5J&N!#WN"D<`,1?Y2ZI5K'RSPW5,
M`LI.Q4V<XN\:X/##$A'2LW+5UW$RA*0W35D"(27YERS]D"&5$BXK"`Z%/H/6
M.[F.J+G30T)=]2YH(=SRX9?])BY>B*[W2Q=EMS7KNT8H;U3;NO4EZ<0TQ1RM
MZXJ&("6N8'ERD%$SPX;QJ>2-;/\`Q^R=Q:SK-&0SWCC$5\8UB5FSJ-Y+)M4A
M*I*M7#=V5WM54O-3(0J4@D<`5=H%*X`NXJNELL5]=6VV6CN2-N4+2''F]&GX
MB,D(">/CQ)QYY^K[TE?^K.Z%C[R]M(7R]J[U>:2600%8J.H=-%(UK"U0::82
M@M>=(;('1@(&X&__`&V29$[[RG42332THN+`$$TRDW!^<N(Z"8NANX_SZYNR
M(XA4U8C!#3(UQS52A`]F#;_EXF=)0;.C*ZVU%4USE74!I:TCAEIS'MQ;,]GO
MOWC_`%`IIIV#L("7U]!Z(77_`$]2<D^_'B2&@.)_*6@)[%S^_'(R(B8#@4HB
M!S#H)A#4#:=]=![Z=8JXN:3P`Q@CGOU2`)I+?<H(^\8IS<@,>9S\0WD&E.5M
M.HKZ\X$O]HML@B^:I+A#.*SD9T,Q;<<S\JW;NB5>Q0TNH"T6Z<E]AP"*8]P,
MH4!5515^V;V;A"S71.>2Y">!S3V\\>\G;/>?;[UZ>F"G[`[JO++3W4M%)`V-
MTQC0RTOZ5.Z",H7Q.@9$V1'`@EXRR.-BYM^:-YDF!I5NX:\@LMX;LA2,VE]P
M_9,7TIQ#GVF46+-Q>112F3@X;J`5!PU+N0>I"!B"B8#`;HWG=U//"R2@?-%5
MAP*/;I!;SS4\//CY8A>G/_&_5[8K+C9O4-MBR7>RR,F=27."Y3QU`(:[2)*9
MNF,M<H<'G-A"$.&!VX)N'?,[F9GCD]FV[T]M>ZUB#)>2&-5062B7]NN0XVDZ
M5$IU*%55444A*?#D,Y<E*H<Z2@I!H("(EYEF`NU^EN-5*PCH/=I!\&H4'DJX
M)7JNBI?3YZ<]J]G.VE%=)-IUUWHZ5U5\$L$-,VLZ\[)Y!&'ATTLA8"3I("GD
M,0QX_.5+;BMQTYT7*)EFK6^W3&F*<78T`%2`O^ZK>_MC5Q*D(8PF`U<A"N9#
M<`"!5$B`.FX.H]DN[+=17#03^HXAB<5<'@%/+GB^>JWLW_[V[Y]N;%(ULVV*
M>OK*ZO<<XQ3T:2LA)X?\C0R(`HH>2.&)D\;/%?R6DJTGR;X6GQW6V%U;R="+
M;KX\K2LI,Q,+*MG,L:'966'ERDC7LTV("CM,2^^LW,'<"@/6S;UJW+2?_P!*
MWMCZ<G];D)3W>XYYXJGK'[U>C.JO,79[O\+Q4U-GG94]&W,<Z)H?#HB8]\<C
M6ZFMS#2/A#@>>!EY*XAY$<+.2+2Q\H8Z"BI_-#6ZV>UOJ2^C%JW:*E?S2=;R
MFPCPCD&$:W<F;2[A95B5$"@J=(P:`(:85--=;9='U=8UO_)!U:2H^)01E@N]
MH.X7:7U%]E);!V>GGEH]N?204C*YO2G@J*!D<](9"]SSH<^-C!,IU%00,Q@J
M.$?+J^^);*EQQ_F"C25NPGE]M7+4TG*TH@4)R+*P*I4<J8TEW2A(>T0\]7)`
MA';,JQ%2'`A!,11(P#,LMWFVQ*Z@N+7_`$+B9`6!?FX$<.0S"Y>*X`GJ%[([
M4]=^S*'=G;:\TU'W3LCZB"2&HTMD<\EG7I*AJ.?$8I(V]-_Q!S7EP:A7'7\B
M'(;QE<F;A=<X8\@.2=SY$9$BH6*CVT@I$TG'4)(0T&S@(60D(MW'3<Y,*,T&
MI1.T9&'Y2P``+$*;J'>[E8K@3547U#ZP$%-):`I3,JO^N)WI6[6>L_LO8[=L
M/=M;LZU]G+54/GJ7O=)55+FF1TT@U-=`V$/<YS=;M67Y#B$<F</+AQM\=$%E
MO*T"M3+?G7DE0AKU<DVOXZ<B:#6,?9*6C7,RP5]L[!Y89&4,Y3;J[546Z:6\
MNXXEZQK]O-MNVV5-4'"JFJ-9"J`T@I[RN83A@J;$]0VVN[7K!J=G[(GAN%AV
MSM&KAGJFO:^.6:HKJ%Q,+P&J(A%I!SS<YO(G$\<8.1/AIJ&`,=UWDOQHLM]S
M;%PTBCD2V1D&_=M)N1/,RCAHX1=-<@PR"^R&6;IF$K=+[R#_`#ZW6^Z[8BI6
MQ5<<CYAQ^!1^.!EWO[7_`.06_=T+O>.TN\;;2=N9YF/HX)*JGB?&UL$;'`L?
M1REIUM<1\9R0KRQM'*69QY,>4_@E*XLC1K^-96F\&Y'&T$Z*"#F(IKV736KD
M2JT.[=&;N6<4=%,2^ZL)3%[G-Z]=2K?35&Z*.:F:X0L;FH3B2A''VXKO8N+<
M=L]%W<V@WI/'5;OBJ]RMK)`X.$U4&SB>1C@&]34\.+"&MU>`P6OF1\=<[0K%
M(<\.,+=]!/&;Y:;S5`54JK.0AI%R51!SEJN`R$#(MW:"RA+`W*4P'*H=QH('
M6#J?NNQOSN=O"2'.0`YE,M0\>2_]\`C_`!\>K*W7RV,],'>R:&HL<Q8VW35"
M%NEKBYM'(YQ1A!SB?F4&E<FKI?\`MNUD5,A<KP1414*:DXI$/CF34*05)VX"
M.XQ.XB)CZB/<!U[=NH7;QLSQ63R`M8)&MSR/RDY#P3GBR_Y=V?2VW9L;FG2V
MJJM.8*L<]NC20<VAOPZLE3ABV=N#3;_\/7_#IH(ZZ_IVZ(73=TDR7'B?EXA?
M^OYXS=98QQI]S+3OV_,C?!K?[1^*8;`%N-&?MGX&T`4_-?F1_%_#_4%_[?U'
MOUJ<ZG>K*@``<W(%]BXFVH74W*+]B$YNX>.G],7"<.Y:>G\9*\$4^&%NMJQX
M<$K:G)1[KQ\FN`NBG0*E;<%*O0DO<'VP1B/S1T`<;A-H4$-=?0->N4_^W"\-
MF%,JY*6?<25X^&&KFNGKMDL/TLO_`++&W1$A<*6[!@:G-PB`+=*YEQR\L>1$
M8I\/:.?'%Y@YOAXKGU_-&7",C<OT(\VE/M6!DW@1=!:W`K&.D#L"'%TD@P(*
MI!.*A1`3:YTS+!'4EU"*0U3@04<PN#?SE`24X:BF-]UW/ZWYNU]+MZ\Q[[':
MZ)I#)9+=6MIW!S@0?JS3C5I<FG]7(D<\34BAXS1:F(B;@[^/!<@*G2<8**T^
M0*:X);MJOLF7V>YM$?N`N[3MKUF&6,3%S12^YS%7V+Q]V*$Z;U>+^J>X?7R4
M].[+I+5'%N;535RY'!=8Z)C5.FP@8E&D#CX&HEK?^GIX56G_``?D+;AA1KIC
M0XM_DBIJ*`[-^[7OKUUFF-\0#$$29(@'NY)@)[J.X7WZH.[?JAN<EOU!K1(*
MA0,NHV;]0$A$U#@GEB-<UI<5S'@/_(HV!O>VR0U,,S*X]*H!=R(2G[?&ZF*;
MNI[8N`0_Q;=_?3K341TKVL%06`!$)*>'!>.2</+%V[?GO*/JCVL.YA&[1]1^
MV"M<`2%BZPI@0U!DS6BI\.-9R6RX6.\65EOE]7C83"J\8@G2OW^^QRRQZ6,]
MK_+C47<TX0@FS;V!^PS!0I=OH.G6B=U&(=$S8.@#Q=I3W%V2>&)^RY._T.]Z
MFKV-_=CNX1>>O](VO=6Z^?6AC:90_P#JUM4Y+B"<*U;Q/0=Q8GP([X0*WY9P
M7\4%$M^(+%;`<F.79^(3934I+(.`4TV"@!3`/IUSZ3^WS*\4[:42)\6DL^_2
M>"X)W<>X>MBMVV^'ND>X[=IY]3Z^GNL=-P_.Z:-L:)_44P7N9$N/PP3#_P`@
MSXA-5PET_P`4&8U*>G`A._%<`E\$;F8L<:6^'[NWV_[WM[]/MUZZ-:VD?%&:
MCIB)I.D.(#3[%P!]@?W]%=Y3VO\`WD[@Z*3?MAJ'3F-1G(*99-.I,W9*F!Q%
M'QAZ#N#@GMT'75S@333ZZZJZ::=0!^TKPI?M9@O]?U<_T]Q?_P`W?^6-XD6W
M!,+I2C2QN+`Y#"+J@XW"0=8J_>00NA!H@4DKA4)H\6!=OXCX6J6FGQ^W70Z=
M!]2UZQ_4`!`H5.2!5]F*O0R>HJ*Q7)MO.]7;;=-5.KM#+D:?J?%]4*AP;TVO
M75UA(01GKYX*&2)!FAY#\X,:6`+'O!F`ESM0B!B@;*?D0E!=#\0T<+03^^"H
M^ULUW]NI=0&$DS\#XY9>_`7HFU!JX!2"47(2`LT.<9NHHT@(=9<NE`,U3RQ`
M^"VW$A)_8_\`QJ-Q_P#G?%C_`-V?Z*.\?KN?A>^Y&,_</[+645!`'0K?'^1V
MW;P+WUZB0_2@_P##Z>DGXM"<>2Z?XX)/<.H[P3QTK>Z@W&(&_%3_`+FRK8WP
C2$U+0"N11F"3[:Z]_3T[Z?\`+37J=FF!@OZ:HU57SY98_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
